{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:38:17Z","timestamp":1792784297991,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Cancer Institute\/National Institutes of Health","award":["R01 CA164335-01A1"],"award-info":[{"award-number":["R01 CA164335-01A1"]}]},{"name":"National Cancer Institute\/National Institutes of Health","award":["R01-CA-025000"],"award-info":[{"award-number":["R01-CA-025000"]}]},{"name":"National Institute of Diabetes and Digestive Kidney Diseases\/National Institutes of Health","award":["R01DK 057830"],"award-info":[{"award-number":["R01DK 057830"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jhep.2016.07.044","type":"journal-article","created":{"date-parts":[[2016,8,10]],"date-time":"2016-08-10T14:49:58Z","timestamp":1470840598000},"page":"75-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model"],"prefix":"10.1016","volume":"66","author":[{"given":"Guangfu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy K.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.","family":"Kimchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego M.","family":"Avella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing X.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Bart","family":"Rountree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussuf T.","family":"Kaifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don C.","family":"Rockey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd D.","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin F.","family":"Staveley-O\u2019Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.07.044_b0005","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2015.02.053","article-title":"The problem of the most appropriate curative treatment for hepatocellular carcinoma. When to embolize? When to operate?","volume":"63","author":"Guerra","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.044_b0010","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2016.07.044_b0015","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.4254\/wjh.v7.i12.1632","article-title":"Guide for diagnosis and treatment of hepatocellular carcinoma","volume":"7","author":"Attwa","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.044_b0020","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2016.07.044_b0025","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2016.07.044_b0030","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1586\/1744666X.2015.1054374","article-title":"Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?","volume":"11","author":"Waqar","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jhep.2016.07.044_b0035","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jhep.2010.10.013","article-title":"Potential of immunotherapy for hepatocellular carcinoma","volume":"54","author":"Breous","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.044_b0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jhep.2013.04.002","article-title":"Facing the dawn of immunotherapy for hepatocellular carcinoma","volume":"59","author":"Sprinzl","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.044_b0045","doi-asserted-by":"crossref","DOI":"10.4172\/2155-9899.1000376","article-title":"Immune-based therapy clinical trials in hepatocellular carcinoma","volume":"6","author":"Liu","year":"2015","journal-title":"J Clin Cell Immunol"},{"key":"10.1016\/j.jhep.2016.07.044_b0050","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1136\/gutjnl-2011-301116","article-title":"Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer","volume":"61","author":"Schneider","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.07.044_b0055","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/gutjnl-2014-307990","article-title":"Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches","volume":"64","author":"Greten","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.07.044_b0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.molonc.2013.01.005","article-title":"Mouse models for liver cancer","volume":"7","author":"Bakiri","year":"2013","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jhep.2016.07.044_b0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/hep.24652","article-title":"Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model","volume":"55","author":"Avella","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.044_b0070","first-page":"2380","article-title":"Smoothened is a master regulator of adult liver repair","volume":"123","author":"Michelotti","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2016.07.044_b0075","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1136\/gutjnl-2014-308041","article-title":"TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice","volume":"64","author":"Martin","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.07.044_b0080","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd3500","article-title":"Cancer immunotherapy\u2013revisited","volume":"10","author":"Lesterhuis","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhep.2016.07.044_b0085","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hep.20644","article-title":"Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells","volume":"41","author":"Unitt","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.044_b0090","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2012-06-435735","article-title":"CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease","volume":"122","author":"Coghill","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2016.07.044_b0095","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/ijc.24556","article-title":"Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients","volume":"125","author":"Zhou","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2016.07.044_b0100","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jhep.2016.07.044_b0105","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1158\/1078-0432.CCR-13-1189","article-title":"Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model","volume":"19","author":"Morales-Kastresana","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2016.07.044_b0110","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1172\/JCI64742","article-title":"Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance","volume":"123","author":"Willimsky","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2016.07.044_b0115","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1053\/j.gastro.2004.09.038","article-title":"Immunotherapeutic strategies for hepatocellular carcinoma","volume":"127","author":"Butterfield","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.07.044_b0120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/j.1460-2075.1989.tb03363.x","article-title":"T antigen expression and tumorigenesis in transgenic mice containing a mouse major urinary protein\/SV40 T antigen hybrid gene","volume":"8","author":"Held","year":"1989","journal-title":"EMBO J"},{"key":"10.1016\/j.jhep.2016.07.044_b0125","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4049\/jimmunol.171.2.697","article-title":"In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice","volume":"171","author":"Staveley-O\u2019Carroll","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2016.07.044_b0130","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jhep.2009.09.008","article-title":"A novel model of CCl4-induced cirrhosis with ascites in the mouse","volume":"51","author":"Domenicali","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.044_b0135","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nm1421","article-title":"CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis","volume":"12","author":"Teixeira-Clerc","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2016.07.044_b0140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.chroma.2007.05.064","article-title":"Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells","volume":"1162","author":"Zheng","year":"2007","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.jhep.2016.07.044_b0145","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/jpet.110.177782","article-title":"Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome","volume":"337","author":"Briest","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2016.07.044_b0150","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.4049\/jimmunol.177.5.3089","article-title":"Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice","volume":"177","author":"Otahal","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2016.07.044_b0155","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.044_b0160","first-page":"3064","article-title":"Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma","volume":"59","author":"Vollmer","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2016.07.044_b0165","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1073\/pnas.96.5.2233","article-title":"Immune surveillance against a solid tumor fails because of immunological ignorance","volume":"96","author":"Ochsenbein","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2016.07.044_b0170","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2016.07.044_b0175","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","article-title":"Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer","volume":"166","author":"Almand","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2016.07.044_b0180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00262-002-0280-8","article-title":"Immature myeloid cells and cancer-associated immune suppression","volume":"51","author":"Kusmartsev","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jhep.2016.07.044_b0185","first-page":"4217","article-title":"The multistep nature of cancer development","volume":"44","author":"Farber","year":"1984","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2016.07.044_b0190","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/sj.onc.1203280","article-title":"The C3(1)\/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma","volume":"19","author":"Green","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2016.07.044_b0195","doi-asserted-by":"crossref","first-page":"11236","DOI":"10.1073\/pnas.91.23.11236","article-title":"Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene","volume":"91","author":"Maroulakou","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2016.07.044_b0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4161\/onci.1.1.18344","article-title":"Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities","volume":"1","author":"Pardee","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jhep.2016.07.044_b0205","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1084\/jem.188.2.341","article-title":"Immune pathogenesis of hepatocellular carcinoma","volume":"188","author":"Nakamoto","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2016.07.044_b0210","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.510270214","article-title":"Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration","volume":"27","author":"Wada","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.044_b0215","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0140-6736(00)02654-4","article-title":"Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial","volume":"356","author":"Takayama","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.07.044_b0220","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1074-7613(02)00480-6","article-title":"Increasing tumor antigen expression overcomes \u201cignorance\u201d to solid tumors via crosspresentation by bone marrow-derived stromal cells","volume":"17","author":"Spiotto","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.jhep.2016.07.044_b0225","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive networks in the tumour environment and their therapeutic relevance","volume":"5","author":"Zou","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2016.07.044_b0230","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-08-4709","article-title":"The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies","volume":"69","author":"Ozao-Choy","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2016.07.044_b0235","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","article-title":"Immunological landscape and immunotherapy of hepatocellular carcinoma","volume":"12","author":"Prieto","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.07.044_b0240","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.smim.2013.04.001","article-title":"Complement inhibition in cancer therapy","volume":"25","author":"Pio","year":"2013","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jhep.2016.07.044_b0245","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.18_suppl.lba101","article-title":"Phase I\/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040","volume":"33","author":"El-Khoueiry","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2016.07.044_b0250","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1182\/blood-2007-02-075945","article-title":"Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses","volume":"111","author":"Hipp","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2016.07.044_b0255","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.canlet.2006.12.014","article-title":"Circulating tumor cells (CTC) detection: clinical impact and future directions","volume":"253","author":"Paterlini-Brechot","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhep.2016.07.044_b0260","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1158\/1078-0432.CCR-10-1105","article-title":"Portable filter-based microdevice for detection and characterization of circulating tumor cells","volume":"16","author":"Lin","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2016.07.044_b0265","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrc2371","article-title":"Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis","volume":"8","author":"Pawelek","year":"2008","journal-title":"Nat Rev Cancer"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816304202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816304202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T20:30:06Z","timestamp":1771965006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816304202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0168827816304202"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.07.044","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.07.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}